Biotech stocks rose last week and beat the broader market, with IBB up 5%, XBI up 4% and XLV up 3%, while SPY fell 0.6% and QQQ dropped 2%. This week, Vertex reports on Monday after the close, with second-quarter sales of $49.6 million for Journavx and $76.4 million for Casgevy. Pfizer (PFE) and Amgen (AMGN) report on Tuesday, Novo Nordisk (NVO) on Wednesday, and Moderna (MRNA) on Friday. Investors will watch Wegovy pill sales, whether Pfizer's newer medicines can offset weaker COVID-related sales, and updates on Amgen's MariTide and Moderna's personalized cancer vaccine. Cancer research will also be presented at the Society for Immunotherapy of Cancer's annual meeting, running November 4 to 8 in Phoenix.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalshealthcarebiotechnologyearningsPfizer
Open a keyword to see other news on the same topic.
Related tickers and likely impact
SPY
• NeutralSPDR S&P 500 ETF
Relevance: low
| Market | US stocks |
|---|---|
| Sector | ETF |
| Close on 10/30/2026 | 755.71 |
| Change that session | -1.77% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Biotech stocks are surging. How investors can play the new drug innovation boom
Biotech stocks are rallying: the iShares Biotechnology ETF (IBB) is up 24% through October 23, after a 28% gain in 2025, with two dozen of its 233 holdings more than doubling year-to-date. Moderna leads with a 587% surge, though its stock fell 18% after a leak of positive cancer-vaccine trial data. Analysts attribute the rally to clinical trial results, M&A, and technologies such as mRNA, genomics and AI, with about a dozen novel biologics approved by the FDA in 2025 out of 46 approvals and roughly 66 novel drugs in the pipeline. The Moderna–Merck melanoma drug showed a 42% reduction in recurrence or death when combined with Keytruda in Phase 3 and is targeted for FDA submission and launch in 2027. Gene-sequencing firm Illumina more than doubled this year, and 10x Genomics rose more than 300%.
- Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
The article compares two healthcare ETFs: PJP, which focuses on pharmaceutical companies, and IBB, which spans 243 biotechnology stocks. IBB has the lower expense ratio at 0.44% versus 0.58% for PJP, while PJP pays higher dividends, $1.13 per share over the trailing 12 months compared with $0.34 for IBB. IBB had a max drawdown of nearly 40% during the 2022 bear market and has a higher beta, indicating more volatility, though it has outperformed PJP over the past year as biotech stocks surged in 2026. PJP has been more stable and has outperformed IBB over five years, with a smaller max drawdown and lower beta. The article concludes that the right choice depends on each investor's goals and risk tolerance.
- Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna shares fell 10% to $214.03 in morning trading as investors took profits after a steep rally tied to its personalized cancer vaccine. In August, Moderna said intismeran autogene, given with Keytruda, met its primary endpoint in a late-stage melanoma trial, sending the stock to its best single-day gain ever. Five-year follow-up from a Phase 2b study showed the combination cut the risk of recurrence or death by 49% versus Keytruda alone. Meanwhile, BioNTech fell 2%, Pfizer rose 0.3%, the iShares Biotechnology ETF slid 2% and the S&P 500 ETF (SPY) dipped 0.1%, pointing to selling concentrated in Moderna. Goldman Sachs raised its price target but kept a Neutral rating, with full melanoma data due at ESMO later this month.
- Rapid Micro Biosystems (RPID) is Rebuilding Credibility After an Ill-Conceived Capital Raise
White Brook Capital's Q3 2026 investor letter highlights Rapid Micro Biosystems (NASDAQ:RPID), a life sciences firm providing automated microbial detection and quality control for biopharmaceutical manufacturing. The stock closed at $0.82 on October 21, 2026, with a $40.94 million market cap, down 71.86% year to date and trading in a 52-week range of $0.76 to $4.94. White Brook says the business has strengthened, margin targets have been met, and the MilliporeSigma relationship is on track. However, the share price has suffered from an ill-conceived equity issuance and concerns that more could follow. The firm believes the share price implies a more pessimistic outlook for next year's cash use than is likely.
- Stock Market Today: Dow Rises As Oil Prices Back Off; Biotech, Pharma Stocks Shine (Live Coverage)
The Dow Jones index wavered on Tuesday as oil prices surged. Netflix and SpaceX shares traded mixed ahead of their late-day earnings releases.
- Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Moderna's market cap is near $90 billion, about 3.6 times BioNTech's under $25 billion, after the two traded at similar levels for nearly the first eight months of 2026. Moderna's shares have risen more than 660% year to date on Phase 3 results for its personalized mRNA cancer vaccine intismeran autogene combined with Merck's Keytruda in melanoma, while BioNTech halted a Phase 2 colorectal cancer study in August because its vaccine proved ineffective, and co-founders Uğur Şahin and Özlem Türeci plan to leave by the end of 2026. Moderna trades above 32 times sales versus BioNTech's roughly 8 times, and analysts are far more bullish on BioNTech: 11 of 15 recommend buying, compared with only 3 of 20 for Moderna, whose average price target sits 52.5% below its share price. The author agrees BioNTech is the smarter pick at current valuations, citing its cash position of roughly $18.6 billion at the end of Q2.
Related markets
Latest news
- Is Australia selling its ANZAC frigate shipyard to China?
The Williamstown shipyard, the last in Victoria able to build and maintain large naval vessels and located near Port of Melbourne, is being sold to EMKC, a property fund manager partly owned by Hong Kong's EMKC Group. A company representative confirmed the purchase contract has been signed, with the value undisclosed, though the site had been listed in 2024 at an estimated AUD 200 million. The deal has raised national security concerns, as the article notes that China's national security and foreign relations law could draw interest from its intelligence agencies, and it is unclear whether the Hong Kong company holds a majority stake. The yard built all 10 ANZAC-class frigates, but most staff were laid off after its last ship was completed in 2016. The sale comes as Australia replaces ANZAC frigates with Japan's New FFM design.
- Asia stocks rise as tech gains ahead of Apple results
Most Asian stocks rose on Monday, led by technology shares, as easing oil prices supported risk appetite while investors awaited Apple's quarterly results amid concerns over heavy AI infrastructure spending. South Korea's KOSPI jumped 2.6%, with SK Hynix up 4% and Samsung Electronics up 1.5%, while Japan's Nikkei 225 pared early losses to gain 0.4%. Intel's nearly 29% plunge on Friday after a disappointing profit outlook had raised concerns about semiconductor and other AI-related earnings. Brent crude fell 2% to $111.15 a barrel and U.S. crude dropped 2.3% to $101.73 as diplomatic efforts to end the U.S.-Israeli war on Iran continued. Australia's S&P/ASX 200 bucked the trend with a 0.5% fall ahead of a Reserve Bank of Australia decision on Tuesday, where a 25 basis point hike to 4.85% is widely expected, its fifth increase this year, after inflation accelerated to 4.3% in September.
- Can SpaceX Overcome the AI Trade Sell-Off?
AI stocks have sold off as investors demand proof that huge AI infrastructure spending will pay off, with results so far mixed. SpaceX's AI sales surged 830% to $7.6 billion in the third quarter, accounting for 52% of total revenue, but capex jumped 185% to $19.6 billion, with 83% allocated to AI. Its Starlink business grew 69% to $5.2 billion, and the company expects capex of up to $40 billion this year. The stock is down about 5% from its $150 opening price and remains below its IPO price, while Alphabet fell about 10% after capex of $51.3 billion and missed sales and earnings estimates. The author considers that investor skepticism about capex could weigh on SpaceX's shares for a while.
- Gold and silver prices today, November 2: Phu Quy, SJC, Bao Tin Manh Hai all update new prices
Domestic gold and silver prices edged up on the morning of November 2, 2026, after a steep decline at the end of October. SJC gold bars at Phu Quy, SJC and Bao Tin Manh Hai were quoted at 135.5–137 million VND per tael to buy and 140 million VND to sell, with Bao Tin Manh Hai's SJC price up 0.1 million VND from the previous session. The SJC sell price is still 4.8 million VND below the October peak of 144.8 million VND. Internationally, spot gold rose to 3,907.35 USD per ounce, and the article cites safe-haven demand and bottom-fishing buying as support near 3,900 USD per ounce. Phu Quy 999 silver bars (1 tael) were quoted at 1.587 million VND to buy and 1.636 million VND to sell.
- Steps down as SACOMBANK General Director, where will Mr. Loic Faussier take up his new role?
On the morning of November 2, SACOMBANK announced senior personnel changes. Its Board of Directors appointed Ms. Nguyen Thi Kieu Anh, a Deputy General Director, as Acting General Director effective November 2, 2026. At the same time, Mr. Loic Faussier stepped down as General Director and will continue with the bank as a Senior Adviser to the Board of Directors. Mr. Faussier joined SACOMBANK in March 2026 as Deputy General Director for risk management, legal and compliance, was named Acting General Director on April 22, and was formally appointed General Director on July 10, 2026 after State Bank of Vietnam approval. He has more than 27 years of experience in finance and banking, including senior roles at HSBC Vietnam, VIB and SeABank.
- The FDI race heats up as the Philippines, Malaysia and India join the competition: What does Finance Minister Ngô Văn Tuấn say about Vietnam's target of attracting 30-40 billion USD a year in disbursed capital?
Finance Minister Ngô Văn Tuấn told the National Assembly, while explaining the draft amendment to the Law on Investment, that competition among countries to attract investment is fierce. He cited the Philippines, Malaysia and India, which are offering incentives in sectors overlapping with Vietnam, such as electronics, computers, phones, semiconductors and digital transformation. Vietnam needs to attract an average of about 30-40 billion USD in disbursed FDI capital per year to reach growth of 10% or more, and total social investment must rise about 2.21 times compared with 2021-2025. The draft focuses incentives on high technology, innovation, digital transformation and technology transfer, ties support to measurable outputs, and sets clear conditions for ending incentives if investors fail to meet their commitments.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.